Skip to content

Main Navigation

  • About us
    • Our team
    • Employee stories
    • Working with us
    • Our principles
    • Mission, vision & values
    • History
    • Corporate Social Responsibility
  • Science & Services
    • Contexts of use
      • Trial design and analyses
      • Program strategies and efficiencies
      • Special/specific populations
      • Special considerations
      • Regulatory interactions
    • Pharmetheus Platforms
      • Model-Informed Drug Development
      • PBPK & PBBM
      • Pharmacometrics
      • QSP
    • Solutions
      • Milestone Analysis
      • Embedded Scientist
      • Expert Advice
      • Training workshop
      • Scientific Publication
    • Specific services
      • Model-Informed Bioequivalence & Biosimilarity
    • Publications
    • Case studies
    • Academic collaborations
  • Careers
  • Events
  • News
  • Contact us
  • LinkedIn

Mechanistic modelling of bioavailability and local immunogenicity after subcutaneous administration within the Open Systems Pharmacology framework

PAGE 31 (2023) Abstr 10497
Pellowe M, Selvaggio G, Chenel M, Sjögren E.
ConferenceImmunologyPBPK/PBBMQSP

Pharmetheus Affiliates

Portrait-of-Moriah-Pellowe_Pharmetheus
Consultant

Moriah Pellowe

See bio
Portrait-of-Gianluca-Selvaggio-Pharmetheus
Consultant

Gianluca Selvaggio

See bio
Portrait-of-Marylore-Chenel_Pharmetheus
Chief Research Officer

Marylore Chenel

See bio
Portrait-of-Erik-Sjogren_Pharmetheus-2
Principal Consultant, PBPK & PBBM Platform Scientific Lead

Erik Sjögren

See bio

Contact

Pharmetheus AB
Kungsängstull 4
753 19 Uppsala, Sweden

Visiting address: Dragarbrunnsgatan 77, 5th floor

info@pharmetheus.com

+46(0)18-51 33 28

Links

  • Home
  • Newsletter
  • LinkedIn
  • Whistleblower
  • Privacy Policy
  • Cookie Policy
  • Consent Preferences

Services

  • Contexts of use
  • Pharmetheus platforms
  • Solutions
  • Case studies
  • Publications

About

Pharmetheus is a consultancy firm helping clients reduce uncertainty in technical and regulatory processes, increasing confidence in the development of new medicines that can improve patients’ lives.